3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
9
Gynecologic
2
Gastrointestinal
2
CNS
2
Breast
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Ovarian Neoplasms
40
Breast Neoplasms
14
Uterine Cervical Neoplasms
13
Melanoma
13
Carcinoma, Non-Small-Cell Lung
13
Pancreatic Neoplasms
11
Colorectal Neoplasms
10
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Stomach Neoplasms
7
Triple Negative Breast Neoplasms
6
Fallopian Tube Neoplasms
6
Esophageal Neoplasms
6
Anus Neoplasms
6
Vaginal Neoplasms
5
Penile Neoplasms
5
Lung Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Carcinoma, Hepatocellular
5
Vulvar Neoplasms
4
Urogenital Neoplasms
4
Urinary Bladder Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma, Synovial
4
Oropharyngeal Neoplasms
4
Neoplasms
4
Multiple Myeloma
4
Mesothelioma
4
Carcinoma, Renal Cell
4
Recurrence
3
Interventions
pembrolizumab
14
Specimen Handling
8
Docetaxel
8
olaparib
7
Nivolumab
7
Gemcitabine
7
Trastuzumab
6
Paclitaxel
6
rucaparib
5
Magnetic Resonance Spectroscopy
5
Early Intervention, Educational
5
Biopsy
5
Standard of Care
4
Cyclophosphamide
4
Carboplatin
4
tisotumab vedotin
3
talazoparib
3
pertuzumab
3
durvalumab
3
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Sirolimus
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Methods
3
Irinotecan
3
Immunoglobulin G
3
Fulvestrant
3
Educational Status
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
fludarabine
×
Gynecologic
×
Clear all
NCT07523529
2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2
Recruiting
72 enrolled
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled